Condensed Consolidated Statements of Cash Flows (USD $) In Thousands	9 Months Ended
	Oct. 02, 2011	Oct. 03, 2010
Operating activities:
Net income	$ 87,394	$ 95,425
Add: net income from discontinued operations and dispositions, net of income taxes	(6,900)	(2,065)
Net income from continuing operations	80,494	93,360
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and lease charges, net	3,340	9,833
Depreciation and amortization	78,718	65,870
Stock-based compensation	9,427	10,352
Amortization of deferred debt issuance costs	2,114	1,906
Losses (gains) on step acquisitions and dispositions, net	200	(28,942)
Amortization of acquired inventory revaluation	432	0
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	17,373	(902)
Inventories, net	(17,660)	(23,171)
Accounts payable	(15,512)	8,776
Excess tax benefit from exercise of equity grants	(9,303)	(82)
Accrued expenses and other	1,834	(16,061)
Net cash provided by operating activities of continuing operations	151,457	120,939
Net cash (used in) provided by operating activities of discontinued operations	(9,108)	14,392
Net cash provided by operating activities	142,349	135,331
Investing activities:
Capital expenditures	(24,979)	(22,882)
Proceeds from dispositions of property, plant and equipment, net	456	11,014
Changes in restricted cash balances	1,123	(1,200)
Payments for acquisitions and investments, net of cash and cash equivalents acquired	(311,269)	(148,988)
Net cash used in investing activities of continuing operations	(334,669)	(162,056)
Net cash provided by investing activities of discontinued operations	32,252	4,567
Net cash used in investing activities	(302,417)	(157,489)
Financing activities:
Payments on debt	(496,000)	(157,846)
Proceeds from borrowings	580,000	261,000
Payments of debt issuance costs	(1,000)	(72)
Payments on other credit facilities	(2,303)	(111)
Payments for acquisition-related contingent consideration	(137)	(136)
Excess tax benefit from exercise of equity grants	9,303	82
Proceeds from stock options exercised	23,670	15,171
Purchases of common stock	(110,004)	(995)
Dividends paid	(23,913)	(24,729)
Net cash (used in) provided by financing activities of continuing operations	(20,384)	92,364
Net cash used in financing activities of discontinued operations	(1,908)	(2,844)
Net cash (used in) provided by financing activities	(22,292)	89,520
Effect of exchange rate changes on cash and cash equivalents	10,376	3,919
Net (decrease) increase in cash and cash equivalents	(171,984)	71,281
Cash and cash equivalents at beginning of period	420,086	179,707
Cash and cash equivalents at end of period	$ 248,102	$ 250,988